Stockreport

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]

Nuvectis Pharma, Inc.  (NVCT) 
PDF receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to t [Read more]